{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:33:03Z","timestamp":1789813983598,"version":"4.0.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1038\/ctg.2016.37","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T11:20:04Z","timestamp":1467890404000},"page":"e179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Successful Treatment of Hepatitis C Virus-associated Oral Lichen Planus by Interferon-free Therapy with Direct-acting Antivirals"],"prefix":"10.14309","volume":"7","author":[{"given":"Yumiko","family":"Nagao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanae","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kawahigashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Sata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210317","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/0091270003258669","article-title":"Global burden of disease (GBD) for hepatitis C.","volume":"44","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"R2-2-20210317","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1245\/s10434-013-3417-4","article-title":"Serum antibody titers against hepatitis C virus and postoperative intrahepatic recurrence of hepatocellular carcinoma.","volume":"21","author":"Uemura","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R3-2-20210317","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int J Cancer"},{"key":"R4-2-20210317","first-page":"40","article-title":"Current status of hepatocellular carcinoma in Japan.","volume":"2","author":"Ikeda","year":"2013","journal-title":"Chin Clin Oncol"},{"key":"R5-2-20210317","doi-asserted-by":"crossref","first-page":"615","DOI":"10.7326\/0003-4819-123-8-199510150-00008","article-title":"Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations.","volume":"123","author":"Gumber","year":"1995","journal-title":"Ann Intern Med"},{"key":"R7-2-20210317","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R8-2-20210317","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R9-2-20210317","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.","volume":"59","author":"Kumada","year":"2014","journal-title":"Hepatology"},{"key":"R10-2-20210317","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/jvh.12312","article-title":"Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.","volume":"21","author":"Omata","year":"2014","journal-title":"J Viral Hepat"},{"key":"R11-2-20210317","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.","volume":"15","author":"Mizokami","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"R12-2-20210317","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1365-2362.1995.tb01966.x","article-title":"Lichen planus and hepatitis C virus in the northern Kyushu region of Japan.","volume":"25","author":"Nagao","year":"1995","journal-title":"Eur J Clin Invest"},{"key":"R13-2-20210317","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1600-0714.1996.tb01726.x","article-title":"Hepatitis C virus infection in Italian patients with oral lichen planus: a prospective case-control study.","volume":"25","author":"Carrozzo","year":"1996","journal-title":"J Oral Pathol Med"},{"key":"R14-2-20210317","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1046\/j.1365-2362.1996.610607.x","article-title":"Development and exacerbation of oral lichen planus during and after interferon therapy for hepatitis C.","volume":"26","author":"Nagao","year":"1996","journal-title":"Eur J Clin Invest"},{"key":"R15-2-20210317","first-page":"237","article-title":"Exacerbation of oral erosive lichen planus by combination of interferon and ribavirin therapy for chronic hepatitis C.","volume":"15","author":"Nagao","year":"2005","journal-title":"Int J Mol Med"},{"key":"R16-2-20210317","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/MEG.0b013e3282f1cc5d","article-title":"Exacerbation of oral lichen planus lesions during treatment of chronic hepatitis C with pegylated interferon and ribavirin.","volume":"20","author":"Grossmann Sde","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R17-2-20210317","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/1756-0500-5-470","article-title":"Analysis of the factors motivating HCV-infected patients to accept interferon therapy.","volume":"5","author":"Nagao","year":"2012","journal-title":"BMC Res Notes"},{"key":"R18-2-20210317","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1128\/JCM.38.11.4171-4179.2000","article-title":"Improved version 2.0 qualitative and quantitative AMPLICOR reverse transcription-PCR tests for hepatitis C virus RNA: calibration to international units, enhanced genotype reactivity, and performance characteristics.","volume":"38","author":"Lee","year":"2000","journal-title":"J Clin Microbiol"},{"key":"R19-2-20210317","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jcv.2006.12.021","article-title":"Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrepCOBAS TaqMan system.","volume":"38","author":"Sizmann","year":"2007","journal-title":"J Clin Virol"},{"key":"R20-2-20210317","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hep.1840190104","article-title":"Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease.","volume":"19","author":"Dusheiko","year":"1994","journal-title":"Hepatology"},{"key":"R21-2-20210317","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.amjmed.2007.06.022","article-title":"Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C.","volume":"120","author":"Kawamura","year":"2007","journal-title":"Am J Med"},{"key":"R22-2-20210317","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/hep.22703","article-title":"Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.","volume":"49","author":"Arase","year":"2009","journal-title":"Hepatology"},{"key":"R23-2-20210317","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1872-034X.2011.00845.x","article-title":"Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy.","volume":"41","author":"Arase","year":"2011","journal-title":"Hepatol Res"},{"key":"R24-2-20210317","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/jmv.21691","article-title":"Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus.","volume":"82","author":"Arase","year":"2010","journal-title":"J Med Virol"},{"key":"R25-2-20210317","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jmv.23777","article-title":"Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C.","volume":"86","author":"Arase","year":"2014","journal-title":"J Med Virol"},{"key":"R26-2-20210317","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0016-5085(99)70595-0","article-title":"Histological improvement of oral lichen planus in patients with chronic hepatitis C treated with interferon.","volume":"117","author":"Nagao","year":"1999","journal-title":"Gastroenterology"},{"key":"R27-2-20210317","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.4254\/wjh.v7.i27.2740","article-title":"Cutaneous manifestations of hepatitis C in the era of new antiviral agents.","volume":"7","author":"Garcovich","year":"2015","journal-title":"World J Hepatol"},{"key":"R28-2-20210317","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcv.2015.09.003","article-title":"Successful treatment of HCV-associated cryoglobulinemia with ombitasvirparitaprevirritonavir, dasabuvir and ribavirin: a case report.","volume":"72","author":"Makara","year":"2015","journal-title":"J Clin Virol"},{"key":"R29-2-20210317","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1601-0825.2008.01441.x","article-title":"Oral lichen planus: controversies surrounding malignant transformation.","volume":"14","author":"Gonzalez-Moles","year":"2008","journal-title":"Oral Dis"},{"key":"R30-2-20210317","doi-asserted-by":"crossref","first-page":"706","DOI":"10.5114\/aoms.2011.24143","article-title":"Cigarette smoking induces overexpression of c-Met receptor in microvessels of oral lichen planus.","volume":"7","author":"Klosek","year":"2011","journal-title":"Arch Med Sci"},{"key":"R31-2-20210317","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1177\/1758834011422556","article-title":"An overview of the c-MET signaling pathway.","volume":"3","author":"Organ","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"R32-2-20210317","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1600-0714.1992.tb01366.x","article-title":"Occurrence of oral leukoplakia and lichen planus in diabetes mellitus.","volume":"21","author":"Albrecht","year":"1992","journal-title":"J Oral Pathol Med"},{"key":"R33-2-20210317","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40257-015-0142-8","article-title":"Prevalence of metabolic syndrome in patients with mucosal lichen planus: a case-control study.","volume":"16","author":"Baykal","year":"2015","journal-title":"Am J Clin Dermatol"},{"key":"R34-2-20210317","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1440-1746.2007.04835.x","article-title":"Insulin resistance and lichen planus in patients with HCV-infectious liver diseases.","volume":"23","author":"Nagao","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"R35-2-20210317","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3892\/br.2012.14","article-title":"Oral verrucous carcinoma arising from lichen planus and esophageal squamous cell carcinoma in a patient with hepatitis C virus-related liver cirrhosis-hyperinsulinemia and malignant transformation: a case report.","volume":"1","author":"Nagao","year":"2013","journal-title":"Biomed Rep"},{"key":"R36-2-20210317","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1471-230X-12-155","article-title":"Candidiasis and other oral mucosal lesions during and after interferon therapy for HCV-related chronic liver diseases.","volume":"12","author":"Nagao","year":"2012","journal-title":"BMC Gastroenterol"}],"container-title":["Clinical and Translational Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ctg201637.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ctg201637","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/01720094-201607000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/ctg201637.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:13:06Z","timestamp":1786547586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01720094-201607000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1038\/ctg.2016.37","relation":{},"ISSN":["2155-384X"],"issn-type":[{"value":"2155-384X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}